DrugPrint® is a sophisticated new system that is set to revolutionise cardiotoxicity profiling of lead drug candidates in the drug discovery process. DrugPrint® has the potential to significantly improve the lead candidate selection process, reducing the costs of drug development while simultaneously reducing the reliance of drug research on animal testing.   » read more

DrugPrint® benefits

• Early indication of arrhythmic and cardiotoxic effects

• Quick data rich reports
  -cost effective
  -reduce data analysis bottleneck

• Reduces reliance on animal testing

Are you interested in partnering with VivoMedica?

We are always interested in transformational technologies that support the radical change required to make real progress.  If you would like to talk to us about such a technology that you have access to, or if you are interested in discussing our technologies, please call us or email to arrange a discussion.